Skip to main content

Table 2 On-going combination immunotherapy trials in urothelial cancer

From: Biomarkers for immunotherapy in bladder cancer: a moving target

Therapy Number Phase Trial ID Est. Completion
Nivolumab +/− Ipilimumab (CheckMate-032) 1150
70
I/II
II
NCT01928394
NCT02553642
December 2018
September 2018
Atezolizumab + MOXR0916 (anti-OX40) +/− Bevacizumab 762 I NCT02410512 August 2018
CPI-444 + Atezolizumab 534 I/Ib NCT02655822 June 2018
Pembrolizumab + PLX3397 (CSF1R) 400 I/II NCT02452424 July 2019
BMS-986106 (anti-LAG3) +/− Nivolumab 360 I/II NCT01968109 October 2019
MK-7684 +/− Pembrolizumab 336 I NCT02964013 March 2020
GSK3174998 (anti-OX40) +/− Pembrolizumab 264 I NCT02528357 January 2020
Pembrolizuamb + Lenvatinib 250 Ib/II NCT02501096 January 2018
Durvalumab + Epacadostat 185 I/II NCT02318277 January 2018
Pembrolizumab + Ramucirumab 155 I NCT02443324 June 2018
Nivolumab + Cabozantinib +/− Ipilimumab 135 I NCT02496208 December 2017
Atezolizumab + Epacadostat 118 I NCT02298153 November 2020
Durvalumab + (Olaparib or Vistusertib or
AZD1775 or AZD4547)
110 I NCT02546661 March 2019
Durvalumab + Tremelimumab + polyICLC (TLR3 agonist) 102 I/II NCT02643303 August 2022
Pembrolizuamb +/− Acalabrutinib 75 II NCT02351739 Summer 2017
Tremelimumab +/− Durvalumab 64 II NCT02527434 October 2018
Ipilimumab + Enoblituzumab (anti-B7-H3) 59 I NCT02381314 March 2018
Atezolizumab + B-701 (FGFR3 inhibitor) 48 Ib NCT03123055 April 2017
Pembrolizumab + Vorinostat 42 I NCT02619253 May 2018
Pembrolizumab + Docetaxel or Gemcitabine 38 I NCT02437370 December 2019
Nivolumab + Enadenotucirev (oncolytic virus) 30 I NCT02636036 June 2018
Avelumab + NHS-IL-12 30 I NCT02994953 April 2018
Pembrolizumab + Paclitaxel 27 II NCT02581982 March 2019
Nivolumab + IFN-γ 15 I NCT02614456 December 2017